Další formáty:
BibTeX
LaTeX
RIS
@article{906610, author = {Panovská, Anna and Doubek, Michael and Brychtová, Yvona and Mayer, Jiří}, article_number = {4}, keywords = {Alemtuzumab;Cyclophosphamide;Doxorubicin; Prednisolone; Prednisone; Vincristine}, language = {eng}, issn = {2152-2650}, journal = {Clinical Lymphoma, Myeloma & Leukemia}, title = {Chronic Lymphocytic Leukemia and Focusing on Epidemiology and Management in Everyday Hematologic Practice: Recent Data From the Czech Leukemia Study Group for Life (CELL)}, volume = {10}, year = {2010} }
TY - JOUR ID - 906610 AU - Panovská, Anna - Doubek, Michael - Brychtová, Yvona - Mayer, Jiří PY - 2010 TI - Chronic Lymphocytic Leukemia and Focusing on Epidemiology and Management in Everyday Hematologic Practice: Recent Data From the Czech Leukemia Study Group for Life (CELL) JF - Clinical Lymphoma, Myeloma & Leukemia VL - 10 IS - 4 SP - 297-300 EP - 297-300 SN - 21522650 KW - Alemtuzumab;Cyclophosphamide;Doxorubicin KW - Prednisolone KW - Prednisone KW - Vincristine N2 - Purpose: Currently, pathogenesis, new prognostic factors, or new therapy in chronic lymphocytic leukemia (CLL) are frequently discussed; however, up-to-date data concerning the incidence and the management of CLL in everyday hematologic practice are still missing. The aim of our study was to find out the accurate epidemiologic situation of CLL and the diagnostic and therapeutic preferences of hematologists in the preselect area: the South Moravian Region (1,127,718 inhabitants, white race). Patients and Methods: The total number of 540 patients (median age at the time of diagnosis, 65 years; sex, 306 men and 234 women) who had been followed in 2008 were included in the analysis. Results: In the years 2006 and 2007, the incidence of CLL was 5.8 and 6.2, respectively, per 100,000; the prevalence was 48 per 100,000. Chronic lymphocytic leukemia treatment was indicated in 194 patients (36%); 93 (17%) of them also underwent the second line of treatment. Of these 194 patients, 64 patients (33%) were given fludarabine-based regimens, and 74 patients (38%) received chlorambucil as a first line of treatment. Thirty patients were treated within clinical trials. Although the treatment was indicated in only one third of patients (36%), new prognostic factors were examined in > 50% of patients. Conclusion: The ascertained incidence of CLL in our region is higher than declared incidence in the past. Evidently, CLL became an often misdiagnosed and underreported disease. ER -
PANOVSKÁ, Anna, Michael DOUBEK, Yvona BRYCHTOVÁ a Jiří MAYER. Chronic Lymphocytic Leukemia and Focusing on Epidemiology and Management in Everyday Hematologic Practice: Recent Data From the Czech Leukemia Study Group for Life (CELL). \textit{Clinical Lymphoma, Myeloma \&{} Leukemia}. 2010, roč.~10, č.~4, s.~297-300. ISSN~2152-2650.
|